IBM's Two-Front Strategy: Monetizing Blockchain Patents While Repairing Investor Confidence
Published on 07/31/2026 at 13:42 | Redaktion boerse-global.de
The arithmetic of IBM's current predicament is stark. Shares closed Thursday at €192.24, down 2.89 percent on the day, leaving the stock 34.36 percent below its June peak of €292.85. The 52-week low of €175.14 sits uncomfortably close, and with annualized volatility running near 86 percent, this remains a stock that demands nerves of steel.
Yet beneath the surface turbulence, two distinct narratives are unfolding — one involving a quiet but significant intellectual property transaction, the other a slow, painstaking effort to rebuild credibility after the worst trading day in the company's history.
A Patent Portfolio Changes Hands
IBM has agreed to sell nearly 1,000 blockchain patents to Circle, the stablecoin issuer behind USDC. The deal encompasses more than 680 patent families covering blockchain technology, banking, insurance, and cloud security, making Circle the largest holder of such patents in the United States. Financial terms were not disclosed.
For Circle, the acquisition bolsters its infrastructure ambitions. The company plans to deploy the portfolio across its USDC stablecoin, its Arc blockchain, and AI-driven financial tools, as well as the Circle Payments Network. Sarah Wilson, Circle's General Counsel and Corporate Secretary, framed the purchase as essential to the firm's mission, describing IBM as a pioneer of technological innovation.
Should investors sell immediately? Or is it worth buying IBM?
For IBM, the transaction represents a pragmatic exercise in unlocking value from dormant assets. The company had built its blockchain patent position since its push into the space in the mid-2010s, and a PatSnap analysis from December 2025 counted 790 such patents in its portfolio. The sale demonstrates how legacy technology firms can monetize intellectual property even as they navigate operational headwinds — and both companies have signaled interest in exploring further collaboration.
The Wound That Still Needs Healing
The patent deal, however welcome, does little to address the core issue weighing on IBM's share price. That distinction belongs to the historic July 14 profit warning, when preliminary second-quarter results fell short of expectations and the stock plunged 25 percent in a single session — eclipsing even the 23.7 percent drop of October 19, 1987, as the worst trading day in company history.
CEO Arvind Krishna attributed the shortfall to weakness in software and infrastructure, with customers deferring budgets in favor of hardware purchases such as memory chips. When final results arrived on July 22, they largely confirmed the preliminary picture without worsening it: adjusted earnings per share came in at $2.93 on revenue of $17.16 billion, both missing LSEG consensus estimates of $2.97 and $17.58 billion, respectively. Krishna pointed to softer sales of Z-series mainframes and transaction software, noting that companies had front-loaded hardware purchases to preempt expected price increases.
Management also trimmed its 2026 revenue outlook to 4 to 5 percent growth at constant currency, down from the more than 5 percent projected in April.
The market's reaction to the confirmed numbers was notably muted — a 2.15 percent decline ahead of the release and a further 0.22 percent drop in after-hours trading. That subdued response suggests the bad news had already been priced in, a signal that the acute phase of panic may have passed.
Hidden Strengths in the Rubble
For all the damage, pockets of the business continue to perform. Software, IBM's highest-margin segment, generated $7.76 billion in revenue, up 5 percent year over year. Hybrid cloud, driven primarily by Red Hat OpenShift, grew 11 percent, with OpenShift's annual recurring revenue reaching $2.2 billion. The data segment expanded 19 percent, buoyed by demand for AI analytics.
Consulting, too, shows encouraging momentum beneath the surface. New bookings grew 6 percent for the second consecutive quarter, with generative AI now accounting for roughly half of all new engagements and over 30 percent of the backlog.
Management's position remains consistent: this is a timing problem, not a structural one. Deferred deals have been postponed rather than lost, and some had already closed early in the third quarter. If the capital expenditure shift toward memory chips and servers reverses as supply constraints ease, the delayed software and consulting contracts could simply arrive a few quarters later.
The Bear Case Has Teeth
Skeptics are not without ammunition. The share collapse triggered an investigation into possible securities fraud, centering on whether management painted too rosy a picture of the pipeline before the warning. Such unresolved legal overhang can cap sentiment regardless of fundamentals.
Balance sheet flexibility has also narrowed. At the end of June, IBM carried $65.27 billion in debt against just $8.13 billion in cash and marketable securities. The first half saw $10.5 billion deployed into acquisitions — purchases that could strengthen the software business but complicate integration and consume financial headroom.
IBM at a turning point? This analysis reveals what investors need to know now.
A Dividend Streak Endures
Amid the turbulence, one constant remains: the quarterly dividend of $1.69 per share, confirmed alongside the earnings release. The payment date is September 10, 2026, with the record date set for August 10. IBM has now paid dividends every year since 1916, one of the longest streaks in the U.S. equity market.
The technical picture offers a cautiously constructive read. The relative strength index sits at 39.4, approaching oversold territory without having reached genuine capitulation. The stock trades 15.81 percent below its 50-day moving average and 17.41 percent below its 200-day average — gaps that historically tend to narrow once selling pressure abates.
Analyst consensus reflects a similar ambivalence. The average price target stands at €212.87, implying upside of roughly 10.7 percent. Of the analysts who have weighed in over the past three months, twelve rate the stock a buy, five recommend holding, and only one says sell — a collective "Moderate Buy" that suggests Wall Street views the selloff as having pushed valuation below fair value.
Management, for its part, projects currency-adjusted revenue growth of 4 to 5 percent and expects free cash flow to rise by approximately $1 billion this year.
The patent sale to Circle provides tangible evidence that IBM can extract value beyond its core software and infrastructure operations. Whether that proves sufficient to restore investor confidence, however, hinges on a simpler question: whether the promised acceleration in new business activity for the second half of the year actually materializes.
Ad
IBM Stock: New Analysis - 31 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
